RESUMEN
Pigment epithelium-derived factor (PEDF) is a multifunctional secreted glycoprotein that displays broad anti-tumor activity based on dual targeting of the tumor microenvironment (anti-angiogenic action) and the tumor cells (direct anti-tumor action). Here, we show that PEDF expression is high in melanocytes, but it is lost during malignant progression of human melanoma. Using a high-throughput analysis of the data from microarray studies of molecular profiling of human melanoma, we found that PEDF expression is lost in highly invasive melanomas. In paired cell lines established from the same lesion but representing the high and low extremes of malignant potential, abundant PEDF expression was restricted to the poorly aggressive counterparts. We used RNA interference to directly address the functional consequences of PEDF silencing. PEDF knockdown in poorly aggressive melanoma cell lines augmented migration, invasion and vasculogenic mimicry, which translated into an increased in vivo metastatic potential. PEDF interference also significantly enhanced the migratory and invasive capability of normal melanocytes and moderately increased their proliferative potential. Our results show that loss of PEDF enables melanoma cells to acquire an invasive phenotype and, therefore, modulation of this multifunctional factor could be critical for the malignant progression of human melanoma.
Asunto(s)
Movimiento Celular , Proteínas del Ojo/metabolismo , Regulación Neoplásica de la Expresión Génica , Melanoma/metabolismo , Proteínas de Neoplasias/metabolismo , Factores de Crecimiento Nervioso/metabolismo , Serpinas/metabolismo , Línea Celular Tumoral , Proteínas del Ojo/genética , Perfilación de la Expresión Génica , Humanos , Melanoma/genética , Melanoma/patología , Invasividad Neoplásica , Metástasis de la Neoplasia , Proteínas de Neoplasias/genética , Factores de Crecimiento Nervioso/genética , Análisis de Secuencia por Matrices de Oligonucleótidos , Serpinas/genéticaRESUMEN
Thrombospondin-1 is the first and most studied naturally occurring protein inhibitor of angiogenesis. Its characteristic multi-domain structure determines thrombospondin-1 divergent functions, which include but are not limited to the regulation of angiogenesis. Below we overview the structural determinants and receptors expressed on the endothelial and other cell types, that are at the root of thrombospondin-1 striking ability to block neovascularization. We specifically emphasize thrombospondin-1 direct apoptotic action on the remodeling vascular endothelium and summarize current knowledge of its pro-apoptotic signaling and transcriptional networks. Further, we provide comprehensive survey of the thrombospondin-based anti-angiogenic strategies with special focus on the combination treatments. We convincingly illustrate how precise knowledge of the pro-apoptotic events and intermediates elicited by thrombospondin in the vascular endothelial cells facilitates the design of the most effective treatment combinations, where the efficacy of thrombospondin-derived compounds is maximized by the partner drug(s) ("complementation" strategies) and provide examples of such fine-tuning of the thrombospondin-based anti-angiogenic treatments.
Asunto(s)
Apoptosis/fisiología , Diseño de Fármacos , Trombospondinas/administración & dosificación , Trombospondinas/uso terapéutico , Secuencia de Aminoácidos , Inhibidores de la Angiogénesis/administración & dosificación , Inhibidores de la Angiogénesis/síntesis química , Inhibidores de la Angiogénesis/uso terapéutico , Animales , Apoptosis/efectos de los fármacos , Quimioterapia Combinada , Humanos , Datos de Secuencia Molecular , Fragmentos de Péptidos/administración & dosificación , Fragmentos de Péptidos/síntesis química , Fragmentos de Péptidos/uso terapéutico , Trombospondinas/síntesis químicaRESUMEN
The design of new therapeutic strategies for cancer treatment is based on the combination of drugs directed against different tumor compartments, including the tumor cells themselves and components of the stroma, such as the tumor vasculature. Indeed, several antiangiogenic compounds have entered clinical trials for use alone or in combination with conventional cytotoxic drugs. Pigment epithelium-derived factor (PEDF) is a multifunctional natural peptide with complex neurotrophic, neuroprotective, antiangiogenic, and proapoptotic biological activities, any of which could potentially be exploited for therapeutic purposes. This review summarizes recent studies that reveal the antitumor potential of PEDF based on its antiangiogenic properties and its newly discovered direct antitumor effects, which involve the induction of differentiation or apoptosis in tumor cells. We also discuss possible therapeutic applications of PEDF, based on these mechanistic insights and on the identification of functional domains that retain specific biological activities.
Asunto(s)
Inhibidores de la Angiogénesis/uso terapéutico , Proteínas del Ojo/uso terapéutico , Neoplasias/terapia , Neovascularización Patológica/prevención & control , Factores de Crecimiento Nervioso/uso terapéutico , Serpinas/uso terapéutico , Animales , Apoptosis , Diferenciación Celular , Humanos , Neoplasias/irrigación sanguínea , Fármacos Neuroprotectores/farmacologíaRESUMEN
Antiangiogenic thrombospondin-1 (TSP1) induces endothelial cell death via a CD95-mediated cascade. We used this signaling pathway, where CD95/Fas is a rate-limiting intermediate, as a target to optimize the efficacy of TSP1 active peptide, DI-TSP. Like TSP1, DI-TSP upregulated endothelial CD95L in vivo. To modulate CD95 levels, we chose chemotherapy agent doxorubicin (DXR). DXR caused sustained upregulation of CD95 in the activated endothelium at 1/100 of the maximal tolerated dose. DI-TSP and DXR synergistically induced endothelial apoptosis in vitro, and in vivo, in developing murine vessels. Fas decoy, TSP1 receptor antibody and Pifithrin, a p53 inhibitor, severely decreased apoptosis and restored angiogenesis by DXR-DI-TSP combination, evidencing critical roles of CD95 and TSP1. Combined therapy synergistically blocked neovascularization and progression of the bladder and prostate carcinoma. Such informed design of a complex antiangiogenic therapy based on the rate-limiting molecular targets is a novel concept, which may yield new approaches to cancer treatment.
Asunto(s)
Doxorrubicina/farmacología , Glicoproteínas de Membrana/metabolismo , Neovascularización Patológica/tratamiento farmacológico , Trombospondina 1/farmacología , Regulación hacia Arriba/efectos de los fármacos , Receptor fas/metabolismo , Animales , Antígenos CD/metabolismo , Apoptosis/efectos de los fármacos , Antígeno CD47 , Células Cultivadas , Progresión de la Enfermedad , Sinergismo Farmacológico , Células Endoteliales/citología , Células Endoteliales/efectos de los fármacos , Células Endoteliales/metabolismo , Proteína Ligando Fas , Humanos , Ratones , Neoplasias/irrigación sanguínea , Neoplasias/metabolismo , Neoplasias/patología , Fragmentos de Péptidos/farmacología , Trombospondina 1/química , Proteína p53 Supresora de Tumor/metabolismo , Cordón Umbilical/citología , Cordón Umbilical/efectos de los fármacos , Cordón Umbilical/metabolismo , Ensayos Antitumor por Modelo de XenoinjertoRESUMEN
Angiogenesis, the growth of new vasculature, is an absolute requirement for the maintenance and progression of the overwhelming majority of the solid tumors. Unraveling the mechanisms that govern this complex biological process has become a central issue not only for understanding of the molecular basis of cancer but also for developing new therapeutic approaches that interfere with neovascularization of the tumor mass. Here we discuss the survival and apoptosis of endothelial cells in the context of vessel formation and regression in response to mediators of angiogenesis produced by tumors. It is the balance between proangiogenic and antiangiogenic molecules in the microenvironment of a vessel in vivo that determines whether the existing vasculature will expand, remain the same, or regress. Here we propose that the vascular endothelial cells themselves interpret and respond to these environmental cues by integrating the activities of the survival and apoptotic pathways within the cell. Thus it is the survival or death of the vulnerable cells that venture out to form new vessels that is the ultimate arbiter of whether neovascularization, as well as the growth of a malignancy that depends on it, succeeds or fails.
Asunto(s)
Sustancias de Crecimiento/metabolismo , Neoplasias/irrigación sanguínea , Neovascularización Patológica/metabolismo , Animales , Apoptosis , Supervivencia Celular , Factores de Crecimiento Endotelial/genética , Factores de Crecimiento Endotelial/metabolismo , Endotelio Vascular/metabolismo , Endotelio Vascular/patología , Genes Supresores de Tumor/genética , Sustancias de Crecimiento/genética , Humanos , Linfocinas/genética , Linfocinas/metabolismo , Neovascularización Patológica/genética , Neovascularización Patológica/patología , Neovascularización Patológica/fisiopatología , Transducción de Señal , Factor A de Crecimiento Endotelial Vascular , Factores de Crecimiento Endotelial VascularRESUMEN
Thrombospondin 1 (TSP1) is a multifunctional protein able to activate TGFbeta and to inhibit angiogenesis in vivo. Although usually thought of as an inhibitor of tumor growth, TSP1 may sometimes be present at high levels during tumor progression, suggesting that tumors can eventually overcome their anti-tumor effects. Using a tet-repressible expression system, we demonstrate that murine TSP1 delayed the onset of tumor growth when produced in the tumor bed by rat fibrosarcoma tumor cells or by stromal fibroblasts coinjected with unmodified C6 glioma tumor cells. Yet upon prolonged exposure to TSP1, tumors came to grow at the same rate in the presence as in the absence of TSP1 and transplantation experiments showed that they had become insensitive to inhibition by TSP1 in both syngeneic and immune compromised hosts. Tumor resistance to TSP1 developed as a result of the in vivo outgrowth of pre-existing tumor cell variants that (1) secreted increased amounts of angiogenic factors that counterbalanced the inhibitory effect of TSP1 on neovascularization and (2) grew more efficiently in the presence of TSP1-activated TGFbeta. These results indicate that prolonged and continuous local delivery of a single multifunctional angiogenesis inhibitor like TSP1 to fast-growing tumors can lead to tumor resistance in vivo by fostering the outgrowth of subpopulations that are a by-product of the genetic instability of the tumor cells themselves.
Asunto(s)
Inhibidores de la Angiogénesis/metabolismo , Neoplasias/metabolismo , Neovascularización Patológica/metabolismo , Trombospondina 1/metabolismo , Factor de Crecimiento Transformador beta/metabolismo , Animales , Northern Blotting , Fibrosarcoma/irrigación sanguínea , Fibrosarcoma/metabolismo , Fibrosarcoma/patología , Glioblastoma/irrigación sanguínea , Glioblastoma/metabolismo , Glioblastoma/patología , Immunoblotting , Inmunohistoquímica , Ratones , Ratones Desnudos , Trasplante de Neoplasias , Neoplasias/irrigación sanguínea , Neoplasias/patología , Ratas , Ratas Endogámicas F344 , Células Tumorales CultivadasRESUMEN
Thrombospondin-1 (TSP-1) is a potent inhibitor of angiogenesis that acts directly on endothelial cells via the CD36 surface receptor molecule to halt their migration, proliferation, and morphogenesis in vitro and to block neovascularization in vivo. Here we show that inhibitory signals elicited by TSP-1 did not alter the ability of inducers of angiogenesis to activate p42 and p44 mitogen-activated protein kinase (MAPK). Rather, TSP-1 induced a rapid and transient activation of c-Jun N-terminal kinases (JNK). JNK activation by TSP-1 required engagement of CD36, as it was blocked by antagonistic CD36 antibodies and stimulated by short anti-angiogenic peptides derived from TSP-1 that act exclusively via CD36. TSP-1 inhibition of corneal neovascularization induced by bFGF was severely impaired in mice null for JNK-1, pointing to a critical role for this stress-activated kinase in the inhibition of neovascularization by TSP-1.
Asunto(s)
Inhibidores de la Angiogénesis/farmacología , Sistema de Señalización de MAP Quinasas/efectos de los fármacos , Proteínas Quinasas Activadas por Mitógenos/metabolismo , Neovascularización Fisiológica/efectos de los fármacos , Trombospondina 1/farmacología , Animales , Apoptosis , Antígenos CD36/fisiología , Capilares/citología , Células Cultivadas/efectos de los fármacos , Córnea/irrigación sanguínea , Inhibidores de Cisteína Proteinasa/farmacología , Factores de Crecimiento Endotelial/farmacología , Endotelio Vascular/efectos de los fármacos , Activación Enzimática/efectos de los fármacos , Factor 2 de Crecimiento de Fibroblastos/farmacología , Flavonoides/farmacología , Proteínas Quinasas JNK Activadas por Mitógenos , Linfocinas/farmacología , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Proteínas Quinasas Activadas por Mitógenos/deficiencia , Proteínas Quinasas Activadas por Mitógenos/genética , Neovascularización Patológica/prevención & control , Fragmentos de Péptidos/farmacología , Fragmentos de Péptidos/uso terapéutico , Factor de Crecimiento Derivado de Plaquetas/farmacología , Trombospondina 1/química , Trombospondina 1/uso terapéutico , Factor A de Crecimiento Endotelial Vascular , Factores de Crecimiento Endotelial VascularRESUMEN
Cyclosporin A (CsA) is an immunosuppressive drug that inhibits the activity of transcription factors of the nuclear factor of activated T cells (NFAT) family, interfering with the induction of cytokines and other inducible genes required for the immune response. Here we show that CsA inhibits migration of primary endothelial cells and angiogenesis induced by vascular endothelial growth factor (VEGF); this effect appears to be mediated through the inhibition of cyclooxygenase (Cox)-2, the transcription of which is activated by VEGF in primary endothelial cells. Consistent with this, we show that the induction of Cox-2 gene expression by VEGF requires NFAT activation. Most important, the CsA-mediated inhibition of angiogenesis both in vitro and in vivo was comparable to the Cox-2 inhibitor NS-398, and reversed by prostaglandin E(2). Furthermore, the in vivo corneal angiogenesis induced by VEGF, but not by basic fibroblast growth factor, was selectively inhibited in mice treated with CsA systemically. These findings involve NFAT in the regulation of Cox-2 in endothelial cells, point to a role for this transcription factor in angiogenesis, and may provide a novel mechanism underlying the beneficial effects of CsA in angiogenesis-related diseases such as rheumatoid arthritis and psoriasis.
Asunto(s)
Ciclosporina/farmacología , Proteínas de Unión al ADN/metabolismo , Factores de Crecimiento Endotelial/antagonistas & inhibidores , Isoenzimas/metabolismo , Linfocinas/antagonistas & inhibidores , Neovascularización Fisiológica/efectos de los fármacos , Proteínas Nucleares , Prostaglandina-Endoperóxido Sintasas/metabolismo , Factores de Transcripción/metabolismo , Inhibidores de la Angiogénesis/farmacología , Animales , Inhibición de Migración Celular , Movimiento Celular/efectos de los fármacos , Células Cultivadas , Córnea/irrigación sanguínea , Córnea/efectos de los fármacos , Ciclooxigenasa 2 , Inhibidores de la Ciclooxigenasa 2 , Inhibidores de la Ciclooxigenasa/farmacología , Dinoprostona/farmacología , Factores de Crecimiento Endotelial/metabolismo , Factores de Crecimiento Endotelial/farmacología , Endotelio Vascular/citología , Endotelio Vascular/efectos de los fármacos , Endotelio Vascular/metabolismo , Regulación de la Expresión Génica/efectos de los fármacos , Genes Reporteros , Humanos , Isoenzimas/antagonistas & inhibidores , Isoenzimas/genética , Linfocinas/metabolismo , Linfocinas/farmacología , Proteínas de la Membrana , Ratones , Ratones Endogámicos C57BL , Mutagénesis Sitio-Dirigida , Factores de Transcripción NFATC , Nitrobencenos/farmacología , Regiones Promotoras Genéticas , Prostaglandina-Endoperóxido Sintasas/genética , Sulfonamidas/farmacología , Transfección , Factor A de Crecimiento Endotelial Vascular , Factores de Crecimiento Endotelial VascularRESUMEN
Recent studies have identified factors responsible for angiogenesis within developing tumors, but mediators of vessel formation at sites of trauma, injury, and wound healing are not clearly established. Here we show that sphingosine 1-phosphate (S1P) released by platelets during blood clotting is a potent, specific, and selective endothelial cell chemoattractant that accounts for most of the strong endothelial cell chemotactic activity of blood serum, an activity that is markedly diminished in plasma. Preincubation of endothelial cells with pertussis toxin inhibited this effect of S1P, demonstrating the involvement of a Galphai-coupled receptor. After S1P-induced migration, endothelial cells proliferated avidly and differentiated forming multicellular structures suggestive of early blood vessel formation. S1P was strikingly effective in enhancing the ability of fibroblast growth factor to induce angiogenesis in the avascular mouse cornea. Our results show that blood coagulation initiates endothelial cell angiogenic responses through the release of S1P, a potent endothelial cell chemoattractant that exerts its effects by activating a receptor-dependent process.
Asunto(s)
Plaquetas/metabolismo , Endotelio Vascular/efectos de los fármacos , Hemostasis/efectos de los fármacos , Lisofosfolípidos , Neovascularización Fisiológica/efectos de los fármacos , Esfingosina/análogos & derivados , Esfingosina/farmacología , Animales , Coagulación Sanguínea , Proteínas Sanguíneas/efectos de los fármacos , Proteínas Sanguíneas/metabolismo , Línea Celular , Carbón Orgánico/farmacología , Quimiotaxis/efectos de los fármacos , Cromatografía en Capa Delgada , Relación Dosis-Respuesta a Droga , Endotelio Vascular/citología , Sustancias de Crecimiento/sangre , Hemostasis/fisiología , Humanos , Cinética , Lípidos/sangre , Lípidos/farmacología , Ratones , Ratones Endogámicos C57BL , Neovascularización Fisiológica/fisiología , Esfingosina/sangreRESUMEN
Smad4/DPC4 (deleted in pancreatic carcinoma, locus 4) is a tumor suppressor gene lost at high frequency in cancers of the pancreas and other gastrointestinal organs. Smad4 encodes a key intracellular messenger in the transforming growth factor beta (TGF-beta) signaling cascade. TGF-beta is a potent inhibitor of the growth of epithelial cells; thus, it has been assumed that loss of Smad4 during tumor progression relieves this inhibition. Herein, we show that restoration of Smad4 to human pancreatic carcinoma cells suppressed tumor formation in vivo, yet it did not restore sensitivity to TGF-beta. Rather, Smad4 restoration influenced angiogenesis, decreasing expression of vascular endothelial growth factor and increasing expression of thrombospondin-1. In contrast to the parental cell line and to control transfectants that produced rapidly growing tumors in vivo, Smad4 revertants induced small nonprogressive tumors with reduced vascular density. These data define the control of an angiogenic switch as an alternative, previously unknown mechanism of tumor suppression for Smad4 and identify the angiogenic mediators vascular endothelial growth factor and thrombospondin-1 as key target genes.
Asunto(s)
Antineoplásicos/metabolismo , Proteínas de Unión al ADN/metabolismo , Genes Supresores de Tumor , Neovascularización Patológica , Neoplasias Pancreáticas/irrigación sanguínea , Transactivadores/metabolismo , Animales , División Celular/efectos de los fármacos , Movimiento Celular , Proteínas de Unión al ADN/genética , Resistencia a Antineoplásicos , Factores de Crecimiento Endotelial/genética , Factores de Crecimiento Endotelial/metabolismo , Endotelio Vascular/metabolismo , Endotelio Vascular/patología , Factor 2 de Crecimiento de Fibroblastos/farmacología , Genes Supresores de Tumor/genética , Humanos , Linfocinas/genética , Linfocinas/metabolismo , Ratones , Ratones Desnudos , Trasplante de Neoplasias , Neoplasias Pancreáticas/genética , Neoplasias Pancreáticas/metabolismo , Neoplasias Pancreáticas/patología , ARN Mensajero/genética , ARN Mensajero/metabolismo , Receptores de Factores de Crecimiento Transformadores beta/metabolismo , Transducción de Señal/efectos de los fármacos , Proteína Smad4 , Trombospondina 1/genética , Trombospondina 1/metabolismo , Transactivadores/genética , Transfección , Factor de Crecimiento Transformador beta/farmacología , Células Tumorales Cultivadas , Factor A de Crecimiento Endotelial Vascular , Factores de Crecimiento Endotelial VascularAsunto(s)
Hematopoyesis , Neovascularización Fisiológica , Animales , Diferenciación Celular , División Celular/efectos de los fármacos , Citocinas/farmacología , Factores de Crecimiento Endotelial/farmacología , Endotelio Vascular/citología , Endotelio Vascular/metabolismo , Neoplasias Hematológicas/etiología , Hematopoyesis/efectos de los fármacos , Humanos , Neovascularización Fisiológica/efectos de los fármacosRESUMEN
Angiogenesis is a process of capillary formation from pre-existing blood vessels. It is tightly controlled by the balance between positive and negative environmental signals--inducers and inhibitors of angiogenesis in such a way that predominance of inducers results in angiogenesis and predominance of inhibitors--in vascular quiescence. Here we discuss the ability of the angiogenic stimuli to promote survival and the pathways they may utilize. We also summarize information available on the signaling events elicited in the endothelial cells by a naturally occurring inhibitor of angiogenesis Thrombospondin-1 (TSP-1), that result in the endothelial cell apoptosis and inhibition of angiogenesis in vivo. This ability to cause programmed cell death in vascular endothelium is not unique to TSP-1. A substantial number of known angiogenesis inhibitors can also trigger apoptosis in the activated endothelial cells. This fact argues for the possibility of apoptosis to be a common denominator for a major fraction of anti-angiogenic molecules. If this is the case, it is equally possible that the ratio between environmental factors that control angiogenesis is interpreted within individual endothelial cell as a balance between pro-apoptotic and survival signals. Thus the relative strength of the death and survival signal or signals determines the fate of endothelial cell and therefore the fate of remodeling vessel.
Asunto(s)
Inhibidores de la Angiogénesis , Supervivencia Celular/efectos de los fármacos , Endotelio Vascular/citología , Neovascularización Fisiológica/fisiología , Trombospondina 1/farmacología , Inhibidores de la Angiogénesis/farmacología , Animales , Apoptosis/efectos de los fármacos , Endotelio Vascular/efectos de los fármacos , Humanos , Modelos Biológicos , Neovascularización Fisiológica/efectos de los fármacosRESUMEN
Thrombospondin-1 (TSP-1) is a naturally occurring inhibitor of angiogenesis that limits vessel density in normal tissues and curtails tumor growth. Here, we show that the inhibition of angiogenesis in vitro and in vivo and the induction of apoptosis by thrombospondin-1 all required the sequential activation of CD36, p59fyn, caspase-3 like proteases and p38 mitogen-activated protein kinases. We also detected increased endothelial cell apoptosis in situ at the margins of tumors in mice treated with thrombospondin-1. These results indicate that thrombospondin-1, and possibly other broad-spectrum natural inhibitors of angiogenesis, act in vivo by inducing receptor-mediated apoptosis in activated microvascular endothelial cells.
Asunto(s)
Apoptosis/fisiología , Antígenos CD36/fisiología , Endotelio Vascular/fisiología , Melanoma Experimental/irrigación sanguínea , Neovascularización Patológica/fisiopatología , Neovascularización Fisiológica/fisiología , Proteínas Proto-Oncogénicas/fisiología , Trombospondina 1/farmacología , Angiostatinas , Animales , Apoptosis/efectos de los fármacos , Antígenos CD36/genética , Caspasas/metabolismo , Endotelio Vascular/efectos de los fármacos , Factor 2 de Crecimiento de Fibroblastos/farmacología , Humanos , Neoplasias Pulmonares/patología , Neoplasias Pulmonares/secundario , Melanoma Experimental/patología , Melanoma Experimental/secundario , Ratones , Ratones Noqueados , Microcirculación , Proteínas Quinasas Activadas por Mitógenos/metabolismo , Neovascularización Patológica/prevención & control , Neovascularización Fisiológica/efectos de los fármacos , Fragmentos de Péptidos/farmacología , Plasminógeno/farmacología , Proteínas Tirosina Quinasas/metabolismo , Proteínas Proto-Oncogénicas/deficiencia , Proteínas Proto-Oncogénicas/genética , Proteínas Proto-Oncogénicas c-fyn , Transducción de Señal/fisiología , Proteínas Quinasas p38 Activadas por MitógenosRESUMEN
In the absence of disease, the vasculature of the mammalian eye is quiescent, in part because of the action of angiogenic inhibitors that prevent vessels from invading the cornea and vitreous. Here, an inhibitor responsible for the avascularity of these ocular compartments is identified as pigment epithelium-derived factor (PEDF), a protein previously shown to have neurotrophic activity. The amount of inhibitory PEDF produced by retinal cells was positively correlated with oxygen concentrations, suggesting that its loss plays a permissive role in ischemia-driven retinal neovascularization. These results suggest that PEDF may be of therapeutic use, especially in retinopathies where pathological neovascularization compromises vision and leads to blindness.
Asunto(s)
Proteínas del Ojo , Neovascularización Patológica/tratamiento farmacológico , Neovascularización Fisiológica/efectos de los fármacos , Factores de Crecimiento Nervioso , Proteínas/farmacología , Proteínas/fisiología , Retina/metabolismo , Neovascularización Retiniana/tratamiento farmacológico , Serpinas/farmacología , Serpinas/fisiología , Animales , Animales Recién Nacidos , Anticuerpos/inmunología , Bovinos , Células Cultivadas , Quimiotaxis/efectos de los fármacos , Medios de Cultivo Condicionados , Factores de Crecimiento Endotelial/metabolismo , Endotelio Vascular/citología , Endotelio Vascular/efectos de los fármacos , Endotelio Vascular/fisiología , Ojo/irrigación sanguínea , Humanos , Linfocinas/metabolismo , Ratones , Neovascularización Patológica/metabolismo , Neovascularización Patológica/patología , Oxígeno/fisiología , Proteínas/genética , Proteínas/inmunología , ARN Mensajero/genética , ARN Mensajero/metabolismo , Ratas , Retina/patología , Vasos Retinianos/crecimiento & desarrollo , Serpinas/genética , Serpinas/inmunología , Células Tumorales Cultivadas , Factor A de Crecimiento Endotelial Vascular , Factores de Crecimiento Endotelial VascularRESUMEN
Keratinocyte growth factor (KGF), also called fibroblast growth factor-7, is widely known as a paracrine growth and differentiation factor that is produced by mesenchymal cells and has been thought to act specifically on epithelial cells. Here it is shown to affect a new cell type, the microvascular endothelial cell. At subnanomolar concentrations KGF induced in vivo neovascularization in the rat cornea. In vitro it was not effective against endothelial cells cultured from large vessels, but did act directly on those cultured from small vessels, inducing chemotaxis with an ED50 of 0.02-0.05 ng/ml, stimulating proliferation and activating mitogen activated protein kinase (MAPK). KGF also helped to maintain the barrier function of monolayers of capillary but not aortic endothelial cells, protecting against hydrogen peroxide and vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) induced increases in permeability with an ED50 of 0.2-0.5 ng/ml. These newfound abilities of KGF to induce angiogenesis and to stabilize endothelial barriers suggest that it functions in microvascular tissue as it does in epithelial tissues to protect them against mild insults and to speed their repair after major damage.
Asunto(s)
Permeabilidad Capilar/efectos de los fármacos , Córnea/efectos de los fármacos , Endotelio Vascular/efectos de los fármacos , Factores de Crecimiento de Fibroblastos , Sustancias de Crecimiento/farmacología , Queratinocitos , Neovascularización Fisiológica/efectos de los fármacos , Animales , Proteínas Quinasas Dependientes de Calcio-Calmodulina/efectos de los fármacos , División Celular/efectos de los fármacos , Movimiento Celular/efectos de los fármacos , Células Cultivadas , Córnea/citología , Endotelio Vascular/citología , Femenino , Factor 10 de Crecimiento de Fibroblastos , Factor 7 de Crecimiento de Fibroblastos , Humanos , Ratas , Ratas Endogámicas F344 , Proteínas Recombinantes/farmacologíaRESUMEN
Mal II, a 19-residue peptide derived from the second type 1 properdin-like repeat of the antiangiogenic protein thrombospondin-1 (TSP-1), was inactive in angiogenesis assays. Yet the substitution of any one of three L-amino acids by their D-enantiomers conferred on this peptide a potent antiangiogenic activity approaching that of the intact 450-kDa TSP-1. Substituted peptides inhibited the migration of capillary endothelial cells with an ED50 of 8.5 nM for the D-Ile-15 substitution, 10 nM for the D-Ser-4 substitution, and 0.75 nM for the D-Ser-5 substitution. A peptide with D-Ile at position 15 could be shortened to its last seven amino acids with little loss in activity. Like whole TSP-1, the Mal II D-Ile derivative inhibited a broad range of angiogenic inducers, was selective for endothelial cells, and required CD36 receptor binding for activity. A variety of end modifications further improved peptide potency. An ethylamide-capped heptapeptide was also active systemically in that when injected i.p. it rendered mice unable to mount a corneal angiogenic response, suggesting the potential usefulness of such peptides as antiangiogenic therapeutics.
Asunto(s)
Aminoácidos/química , Neovascularización Patológica/prevención & control , Oligopéptidos/farmacología , Trombospondina 1/farmacología , Acetilación , Secuencia de Aminoácidos , Animales , Movimiento Celular/efectos de los fármacos , Factores de Crecimiento Endotelial/farmacología , Endotelio Vascular/citología , Endotelio Vascular/efectos de los fármacos , Factor 1 de Crecimiento de Fibroblastos/farmacología , Factor 2 de Crecimiento de Fibroblastos/farmacología , Interleucina-8/farmacología , Isoleucina/química , Linfocinas/farmacología , Ratones , Ratones Endogámicos C57BL , Datos de Secuencia Molecular , Oligopéptidos/química , Factor de Crecimiento Derivado de Plaquetas/farmacología , Ratas , Ratas Sprague-Dawley , Secuencias Repetitivas de Ácidos Nucleicos , Sensibilidad y Especificidad , Serina/química , Estereoisomerismo , Trombospondina 1/química , Factor A de Crecimiento Endotelial Vascular , Factores de Crecimiento Endotelial VascularRESUMEN
Interleukin (IL)-4, a crucial modulator of the immune system and an active antitumor agent, is also a potent inhibitor of angiogenesis. When incorporated at concentrations of 10 ng/ml or more into pellets implanted into the rat cornea or when delivered systemically to the mouse by intraperitoneal injection, IL-4 blocked the induction of corneal neovascularization by basic fibroblast growth factor. IL-4 as well as IL-13 inhibited the migration of cultured bovine or human microvascular cells, showing unusual dose-response curves that were sharply stimulatory at a concentration of 0.01 ng/ml but inhibitory over a wide range of higher concentrations. Recombinant cytokine from mouse and from human worked equally well in vitro on bovine and human endothelial cells and in vivo in the rat, showing no species specificity. IL-4 was secreted at inhibitory levels by activated murine T helper (TH0) cells and by a line of carcinoma cells whose tumorigenicity is known to be inhibited by IL-4. Its ability to cause media conditioned by these cells to be antiangiogenic suggested that the antiangiogenic activity of IL-4 may play a role in normal physiology and contribute significantly to its demonstrated antitumor activity.
Asunto(s)
Inmunosupresores/farmacología , Interleucina-4/fisiología , Neovascularización Fisiológica/inmunología , Adenocarcinoma , Animales , Movimiento Celular/efectos de los fármacos , Movimiento Celular/inmunología , Células Cultivadas , Córnea/irrigación sanguínea , Córnea/efectos de los fármacos , Córnea/inmunología , Medios de Cultivo Condicionados/química , Medio de Cultivo Libre de Suero/química , Endotelio Vascular/citología , Endotelio Vascular/efectos de los fármacos , Endotelio Vascular/inmunología , Humanos , Inyecciones Intraperitoneales , Interleucina-4/administración & dosificación , Neoplasias Mamarias Experimentales , Ratones , Ratones Endogámicos BALB C , Neovascularización Fisiológica/efectos de los fármacos , Ratas , Células Tumorales CultivadasRESUMEN
Concomitant tumor resistance refers to the ability of some large primary tumors to hold smaller tumors in check, preventing their progressive growth. Here, we demonstrate this phenomenon with a human tumor growing in a nude mouse and show that it is caused by secretion by the tumor of the inhibitor of angiogenesis, thrombospondin-1. When growing subcutaneously, the human fibrosarcoma line HT1080 induced concomitant tumor resistance, preventing the growth of experimental B16/F10 melanoma metastases in the lung. Resistance was due to the production by the tumor cells themselves of high levels of thrombospondin-1, which was present at inhibitory levels in the plasma of tumor-bearing animals who become unable to mount an angiogenic response in their corneas. Animals carrying tumors formed by antisense-derived subclones of HT1080 that secreted low or no thrombospondin had weak or no ability to control the growth of lung metastases. Although purified human platelet thrombospondin-1 had no effect on the growth of melanoma cells in vitro, when injected into mice it was able to halt the growth of their experimental metastases, providing clear evidence of the efficacy of thrombospondin-1 as an anti-tumor agent.
Asunto(s)
Fibrosarcoma/irrigación sanguínea , Fibrosarcoma/patología , Neoplasias Experimentales/irrigación sanguínea , Neoplasias Experimentales/patología , Neovascularización Patológica/fisiopatología , Trombospondina 1/fisiología , Animales , Fibrosarcoma/fisiopatología , Humanos , Ratones , Ratones Desnudos , Metástasis de la Neoplasia , Neoplasias Experimentales/fisiopatología , Neovascularización Patológica/prevención & control , Trombospondina 1/farmacologíaRESUMEN
Bladder tumors are characterized by markedly increased angiogenesis when compared to the normal urothelium (NU) from which they are derived. Here, we use both cultured cells and immunohistochemistry to demonstrate a primary regulatory role for thrombospondin-1 (TSP-1), a potent inhibitor of angiogenesis, in the development of bladder tumor angiogenesis. Secretions from bladder cancer (CA) cells stimulated endothelial cell migration and corneal neovascularization, whereas those from NU cells were inhibitory. The antiangiogenic activity of NU cells was primarily due to secreted TSP-1 because neutralizing antibodies completely relieved the inhibition. Neutralizing antibodies to several putative angiogenesis inducers identified vascular endothelial growth factor (VEGF) and, to a lesser extent, basic fibroblast growth factor as the primary inducers secreted by bladder cancer cells. The secretion of TSP-1 by low- and high-grade cancer cells was reduced >94% when compared to NU cells, and this loss of inhibitory TSP-1 accounted for the development of an angiogenic phenotype because both NU cells and cancer cells secreted similar levels of total stimulatory activity and VEGF. Immunohistochemistry showed that TSP-1 was significantly reduced in all grades of bladder cancer when compared to NU, whereas VEGF staining remained relatively constant. Taken together, these data suggest that down-regulation of TSP-1 secretion is a key event in the switch from an antiangiogenic to an angiogenic phenotype, which occurs early in the development of bladder cancer.
Asunto(s)
Factores de Crecimiento Endotelial/fisiología , Factor 2 de Crecimiento de Fibroblastos/fisiología , Linfocinas/fisiología , Neovascularización Patológica , Trombospondina 1/fisiología , Neoplasias de la Vejiga Urinaria/irrigación sanguínea , Células Cultivadas , Regulación hacia Abajo , Humanos , Células Tumorales Cultivadas , Urotelio/citología , Factor A de Crecimiento Endotelial Vascular , Factores de Crecimiento Endotelial VascularRESUMEN
As normal cells progress to malignancy they must acquire an angiogenic phenotype that will enable them to attract the blood vessels necessary to support their progressive growth. Here we define the mechanism by which human fibroblasts cultured from Li Fraumeni patients and progressing to tumorigenicity in vitro become angiogenic. Initially cells were anti-angiogenic due to the secretion of high levels of inhibitory thrombospondin that overrode the modest amounts of the major inducer, vascular endothelial cell growth factor (VEGF), that were also produced. Cells became fully angiogenic in two steps, the first dependent on the loss of both alleles of wild-type p53 which caused a drop of at least 20-fold in secreted thrombospondin and a fourfold increase in secreted VEGF. Angiogenic activity increased again upon transformation by activated ras due to a further twofold increase in VEGF. Changes in relative levels of VEGF mRNA were sufficient to account for changes in secreted protein levels and in overall angiogenic activity. These studies demonstrate that an angiogenic phenotype able to support tumorigenicity can arise in a step-wise fashion in response to both oncogene activation and tumor suppressor gene loss and involve both a decrease in the secretion of inhibitors and the sequential ratcheting up of the secretion of inducers of angiogenesis.